Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Effect of obstructive sleep apnea treatment on renal function in patients with cardiovascular disease|
|Citation:||American journal of respiratory and critical care medicine, 2017; 196(11):1456-1462|
|Publisher:||American Thoracic Society|
|Kelly A. Loffler, Emma Heeley, Ruth Freed, Craig S. Anderson, Ben Brockway, Alastair Corbett, Catherina L. Chang, James A. Douglas, Katherine Ferrier, Neil Graham, Garun S. Hamilton, Michael Hlavac, Nigel McArdle, John McLachlan, Sutapa Mukherjee, Matthew T. Naughton, Francis Thien, Alan Young, Ronald R. Grunstein, Lyle J. Palmer, Richard J. Woodman, Patrick J. Hanly, and R. Doug McEvoy|
|Abstract:||Rationale: Obstructive sleep apnea (OSA) is associated with impaired renal function, but uncertainty exists over whether OSA treatment can influence renal outcomes. Objectives: To determine the effects of continuous positive airway pressure (CPAP) on renal function in subjects with coexisting OSA and cardiovascular disease. Methods: This was a substudy of the international SAVE (Sleep Apnea Cardiovascular Endpoints) trial, in which 2,717 patients with moderate to severe OSA and established coronary or cerebrovascular disease were randomized to receive either CPAP plus usual care or usual care alone. Renal function and adverse renal events were compared between the CPAP (n = 102) and usual care (n = 98) groups. Glomerular filtration rate was estimated at randomization and at the end of follow-up, and the urinary albumin-to-creatinine ratio was measured at study exit. Measurements and Main Results: In 200 substudy participants (mean age, 64 yr; median, 4% oxygen desaturation index; 20 events/h; mean estimated glomerular filtration rate at baseline, 82 ml/min/1.73 m2), the median (interquartile range) changes in estimated glomerular filtration rate (ml/min/1.73 m2/yr) were -1.64 (-3.45 to -0.740) in the CPAP group and -2.30 (-4.53 to -0.71) in the usual care group (P = 0.21) after a median of 4.4 years. There were no between-group differences in end-of-study urinary albumin-to-creatinine ratio or in the occurrence of serious renal or urinary adverse events during the trial. The level of CPAP adherence did not influence the findings. Conclusions: CPAP treatment of OSA in patients with cardiovascular disease does not alter renal function or the occurrence of renal adverse events.|
|Keywords:||Obstructive sleep apnea; continuous positive airway pressure; randomized controlled trial; glomerular filtration rate; albuminuria|
|Rights:||Copyright © 2017 by the American Thoracic Society|
|Appears in Collections:||Public Health publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.